Food allergy is an adverse reaction to otherwise harmless proteins in food. The disease is a major health problem of growing concern, affecting approximately 5%-8% of young children and 2%-4% of adults. No accepted strategy exists for prevention and treatment of food allergy, and strict avoidance of the offending food is pre- With the increased appreciation that food allergy is a heterogeneous disease presenting different phenotypes, there is a continued need to develop new diseaserelevant therapeutic models of food allergy.
| INTRODUCTION
Food allergy is an immune-mediated hypersensitivity to specific proteins in food, which occur as a result of allergic sensitization due to a failure of the immune system to develop tolerance after first exposure, or the abrogation of an already established tolerance. The prevalence of food allergy is estimated to be around 5%-8% in young children and around 2%-4% in adults in the Western world 1 and appears to be a rising problem. 1, 2 Most cases of food allergy is mediated by IgE-dependent immediate hypersensitivity reactions;
however, some rarer food allergies may also involve cell-mediated sensitization with and without the contribution of IgE (extensively reviewed in Ref. [3, 4] ). Ingestion of disease-triggering foods in sensitized individuals can cause an array of symptoms in the gastrointestinal tract (pain, nausea, vomiting and diarrhoea), skin (itchiness, urticarial and angioedema), respiratory and cardiovascular systems (dyspnoea, wheezing and tachycardia). 5 In severe cases, allergic reactions can cause acute respiratory and cardiac arrest. The first line of management involves food avoidance, and acute systemic reactions are treated with epinephrine, which are often carried by patients with severe allergy in case of accidental ingestion. The lack of treatment options, restrictive food avoidance and the prospect of accidental ingestion make food allergy a chronic disease that significantly impacts the quality of life for patients. 6 Allergen-specific immunotherapy (IT) is emerging as a viable option for human desensitization with the ability to increase thresholds of reactivity, as demonstrate by a recent systematic meta-analysis of 31 clinical trials in food allergy. 7 However, current immunotherapeutic regimens are typically lengthy with repeated, increasing doses of allergen, and the risk of acute adverse reactions.
Furthermore, current regimens are largely unable to induce complete clinical tolerance. Thus, there is a need to develop better regimens of allergen-specific IT. Testing therapies in animal disease models are central to evaluating the potential of new immunotherapeutic strategies or modified versions of current regimens. Here, we present a comprehensive overview of animal models of food allergy therapy currently reported in the literature and highlight opportunities for new avenues of study and model improvements. This review will primarily address IT in animal models using allergens and allergen challenges of relevance to clinical food allergy outcomes. A detailed overview of the presented therapeutic animal models can be found
in Table 1 and summarized in Figure 1 . Currently, most models have been developed in mice exploring oral therapy with dosaging of native protein, and to some extent less allergenic preparations containing hydrolyzed allergen and immunodominant T cells epitopes.
Models using epicutaneous (EPIT) or subcutaneous immunotherapy
(SCIT) have in recent years received increased attention due to possible better safety and efficacy of these routes compared to oral administration. Additionally, models exploring therapy using immunomodulatory adjuvants or cell therapy have been developed.
Current studies have addressed several immunological and clinical outcomes of therapy (summarized in Figure 2 ). However, most models only assess the acute anaphylaxis outcome of food allergy by temperature loss and clinical severity scoring. With the increased appreciation that food allergy is a heterogeneous disease presenting with different phenotypes and mechanisms in relation to foods, exposure, symptoms and natural history, 8 there is a continued need to develop new disease-relevant therapeutic models in food allergy.
| ORAL IMMUNOTHERAPY
The default outcome of ingesting food is for the immune system to tolerate the exposure to the foreign antigens contained within. The concept of oral tolerance has been studied in rodents since 1910, with early studies describing how oral ingestion of antigen would inhibit later experimental hyperactivity, thus demonstrating that tolerance to ingested food involves active antigen-specific suppression of hypersensitivity. 9 Several later studies have addressed the mechanistic basis of oral tolerance, including a pivotal role of regulatory T cells (reviewed in Ref. [10, 11] ). Oral IT (OIT) models have been developed using egg white, 12 ovomucoid (native or heated), 12 ovalbumin, 13 cow's milk proteins (CMPs) 14 , 15 and peanut [15] [16] [17] in sensitized mice. In these studies, therapy was able to reverse or ameliorate food challenge-induced anaphylaxis and clinical disease scores, when mice were challenged immediately after treatment.
However, some studies found, 12, 13, 17 that the desensitization was short-term as sensitization returned within 2-5 weeks after therapeutic cessation. These findings are in line with oral immunotherapy trials in humans reporting limited effects on the induction of sustained unresponsiveness in food allergic individuals. The OIT models found varying effect on the levels of allergen-specific IgG reporting similar, 12-14 decreased 17 or increased 15 IgG1 levels, and similar [12] [13] [14] or increased 13, 15, 16 IgG2a levels. The therapeutic effect on allergenspecific IgE levels were similarly diverse with similar, 13 12 Similar results were observed in another study where peanut and whey OIT suppressed mast cell responses following oral challenge, but only mice receiving peanut OIT were protected from intraperitoneal (IP) induced anaphylaxis, indicating allergen-specific differences in therapeutic outcomes and mechanisms. 15 The therapeutic suppression of local gastrointestinal allergic responses was proposed to be mediated by increased IgA levels induced by treatment; however, this hypothesis remains to be formally investigated.
12
Oral therapy was also associated with increased gastrointestinal permeability and changes in transcriptional profile in proximal jejunum. 12 The significance of these treatment-induced changes remain to be investigated, but may reflect the adverse gastrointestinal effects reported in human clinical trials.
Allergen-specific ex vivo production of T-cell-related type-2 13 and ex vivo allergen-specific IL-10 was suppressed in mice receiving OIT. 12 These results suggest the induction of different immune regulatory mechanisms in the therapeutic response to different allergens or regimens. The study using peanut IT 16 found, that the expansion of regulatory T cells was abrogated 8 weeks posttherapy, and the induced regulatory T cells were unable to transfer desensitization to sensitized mice. These findings suggest that the short-term desensitization in these models is due to the unstable induction of regulatory T cells. Interestingly, a study combining ingly, in these models challenges were performed IP 2-5 weeks posttreatment indicating long-term efficacy of therapy. These findings are opposed to the studies of OIT reviewed above, in which efficacy to oral challenges was lost 2-4 weeks post-treatment and allergic reactivity was sustained in response to IP (systemic) challenge for ovalbumin and whey OIT. 12, 15 This indicates that the therapeutic tolerance induced via the oral route is different from tolerance generated via IP allergen administration. It could be speculated that oral allergen administration subverts long-term protection by chronic activation of IgE-dependent mechanisms, as indicated in the case of oral peanut desensitization in combination with anti-IgE. 17 However, more experimental work comparing administration routes using the same allergens, sensitization and challenge protocols are required to address this hypothesis. Furthermore, the role of regulatory T cells in IPIT models remains to be investigated. OIT using digested and undigested protein needs to be compared head-to-head to determine altered efficacy, reduced adverse effects and mechanism of desensitization.
| IMMUNOTH ERAPY USING HYDROLYZED FOOD PROTEINS

| T -CE LL-DIRECTED PEPTIDE IMMUNOTHERAPY
Immunotherapy using specific peptides may be a more specific alternative to the use of digested or hydrolyzed food proteins allowing a consistent and well-defined therapy. Several studies have systematically assayed specific peptides from allergens to identify T-cell epitopes by the means of stimulating immune cells from sensitized animals or allergic patients followed by measuring proliferation or cytokine production. Allergen immunodominant T-cell epitopes have been identified for several food allergens for mice (ovalbumin, 24 shrimp tropomyosin 28 and beta-lactoglobulin. 36 The studies of ovomucoid and beta-lactoglobulin reported a therapeutic effect of single peptide administration (15-and 22-mers), 35, 36 whereas none of three different peptides (15-mers) in the ovalbumin study had an effect when administered individually. 34 However, administration of the three ovalbumin peptides as a cocktail significantly ameliorated F I G U R E 2 Overview of clinical and immunological outcomes assessed within allergen-specific immunotherapy models in food allergy.
Outcomes have been divided into clinical (symptoms), para-clinical (histology) and immunological (serology, systemic and tissue immune responses) measures F I G U R E 1 Overview of allergen-specific immunotherapy models in food allergy. Flowcharts show models in relation to a particular food allergy (egg, cow's milk, peanut, tree nut and shrimp) with the specific allergen, mode of sensitization and therapy used. The thickness of lines shows the number of models reported using the specific approach (1) (2) (3) (4) (5) (6) (7) (8) . increased allergen-specific IL-10 production and systemic CD4 + FoxP3 + regulatory T-cell numbers. 35 The study using peptide IT in beta-lactoglobulin sensitized mice was unable to report therapeutic effects on antibody levels (allergen-specific IgE, IgG1, clear allergen-or therapy-related patterns could be observed suggesting diverse underlying immunological mechanisms. 15 Other SCIT mouse models using food allergens support efficacy, but have been conducted without oral or IP allergen provocations for the assessment of clinical food allergy outcomes. Studies using ovalbumin or peanut SCIT found therapy to suppress allergen-specific IgE and increase IgG2a in serum. 40, 41 In line, SCIT treated animals exhibited decreased airway hyperreactivity and suppressed type-2 immune responses in the lung following airway allergen challenge. Additional mechanistic studies in SCIT models employing clinical food allergyrelated outcomes are needed, including therapeutic duration, and adverse reactions compared to OIT.
| EPICUTAN EOUS IMMUNOTHERAPY
Epicutaneous IT (EPIT) has recently emerged as a new mode of allergen delivery in food allergy therapy. It was hypothesized that applying allergen onto intact skin would allow controlled diffusion, and reduce risk of systemic allergen dissemination and anaphylaxis. To this end, DBV Technologies developed an epicutaneous delivery system (Viaskin patch) that consists of a chamber that releases allergen onto the skin, 41 where it diffuses into the epidermis and is taken up by dendritic cells that migrates to draining lymph nodes and induce allergen-specific regulatory T cells. 42 Early studies found that EPIT could suppress allergen-specific IgE and type-2 immune responses, and increase allergen-specific IgG2a in ovalbumin, 41, 42 peanut, 40, 41 CMP, 43 house dust mite 41 and pollen 41, 44 sensitized mice. The first studies of EPIT in relation to food allergy outcomes were conducted in models of oesophago-gastro-enteropathy following long-term allergen exposure in sensitized animals. EPIT was found to completely reverse oesophageal and gastric eosinophilia, and reduce serum allergen-specific IgE in peanut-sensitized mice 45, 46 and pigs. 
| SUBLINGUAL IMMUNOTHERAPY
Sublingual IT involves administration of allergen under the tongue followed by swallowing. This therapeutic route is commonly used in the treatment of allergic rhinitis and asthma with demonstrated efficacy in humans. 49 Clinical trials of SLIT in food allergy has been conducted in humans, but indicated reduced efficacy in the treatment of peanut and cow's milk allergy compared to OIT. 50, 51 To our knowledge, only one therapeutic animal model using SLIT in relation to food allergy outcomes has been published. The study was published very recently demonstrating clinical efficacy of SLIT in cow's milk sensitized mice using low dosages of allergen (pg to ng range). 
| IMMUN OTHERAPY USING IMMUNOMODULATORY ADJUVANTS
Adjuvants are commonly used in vaccines to elicit a desired immunological response. Therapeutic studies in food allergy models have explored the ability of adjuvants to skew the allergic type-2 immune response towards a type-1 response using TLR9 agonists [54] [55] [56] [57] or heat-killed (HK) bacteria. 58, 59 Two of the studies using TLR9 agonists were performed in mice sensitized to peanut using OIT 56 with whole peanut or peanut protein extract. 54, 55 The studies addressing the role of HK bacterial adjuvants were performed using subcutaneous or per rectum (PR) IT using recombinant Ara h 1-3 proteins with modified epitopes reducing IgE binding in peanut-sensitized mice. 58, 59 The studies reported similar results with suppression of oral challengeinduced anaphylaxis, reduced allergen-specific IgE and increased IgG2a in groups receiving adjuvant allergen-specific therapy. Allergen- 56 Two studies performed several oral challenges indicating therapeutic efficacy for up to 10-16 weeks posttreatment. 55, 59 Combined, these findings indicate that Th1-driving adjuvants promote allergen-specific Th1 cells with a stable phenotype. Another study using TLR9 agonist in intradermal IT in ovalbumin-sensitized mice found limited effect on anaphylaxis scores and temperature loss, but indicated improved survival following challenge. 57 This finding may indicate allergen-specific differences or reflect different treatment regimens. The role of regulatory T cells in these models remains largely unknown. One study using TLR9 agonist found no therapeutic effect on allergen-specific TGF-β levels, 55 whereas one model using HK bacterial reported increased allergenspecific TGF-β. 59 As HK bacteria contain several ligands stimulating innate immunity, it cannot be excluded that agonists targeting other pathogen-associated molecular pattern receptors than TLR9 can be involved in promoting regulatory T cells. Thus there is an opportunity to study the role of other adjuvants in these models to identify alter- previously been found to suppress type-2 immune responses and challenge-induced anaphylaxis. 60 Thus, combining probiotics and allergen-specific IT may lead to improved efficacy.
A recent study employed a synthetic cetylpyridinium chloride and oil-based nanoemulsion adjuvant with type-1/17 driving properties for nasal peanut IT in mice. 61 The adjuvant was found to promote suppression of challenge-induced anaphylaxis, allergen-specific 
| CELLULAR IMMUNOTHERAPY
IT using immune cells has been used in the clinic to promote anticancer immunity, commonly by administrating ex vivo expanded effector T cells or dendritic cells carrying cancer antigens. 63 To our knowledge, cellular IT has not been applied in clinical allergy, which likely is reflected by the very few studies of this therapeutic approach in food allergy animal models. The generation and transfer of allergen-specific regulatory T cells could be a potential therapy.
This was recently explored in a model of peanut allergy where mice received regulatory T cells from mice having received OIT, SLIT or EPIT with peanut. 16 The study found that EPIT-induced regulatory T cells could suppress the elicitation of oesophageal eosinophilia. Cellular IT is in its infancy within food allergy, and inspiration could be taken from the experiences in the field of autoimmunity, which aims to suppress the pathological Th1/17 response and promote regulatory T cells. 65 Models using other immune cell phenotypes for therapy, as well as optimizing the approach in terms of cell preparation, route of delivery and adjuvants may be needed.
| CONCLUSION
Animal models of food allergen-specific IT are widely used as a preclinical approach to study the efficacy of new therapeutic strate- should include other disease-relevant clinical outcomes in addition to acute anaphylaxis, including diarrhoea, respiratory function and gastrointestinal pathology. Intriguingly, the models presented underline a possible role of allergen-specific differences in therapeutic outcomes, mechanisms and even sensitization. In line, the skin has been indicated as a route of sensitization for which models have recently been developed. 13 It remains however largely unknown how the route (oral, IP, skin or respiratory) or method of sensitization (adjuvant use or genetically susceptible mice) affects therapeutic outcomes in the presented IT models. Animal models will in the future remain a valuable tool to study efficacy and mechanisms in different food allergy phenotypes in a controlled manner.
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